Immunic to Participate in Investor Conferences in March
MWN-AI** Summary
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology firm specializing in novel oral therapies for neurologic and gastrointestinal diseases, will participate in two significant investor conferences in March 2026. From March 8-11, the company will be at the Leerink Partners Global Healthcare Conference in Miami, where CEO Daniel Vitt, Ph.D., and COO Jason Tardio will engage in a fireside chat on March 11 at 10:40 AM ET. Participants will have access to a webcast of this discussion through Immunic’s website. Additionally, the executives and Jessica Breu, VP of Investor Relations, will hold one-on-one investor meetings to discuss corporate strategies and clinical developments.
The second event is the Stifel 2026 Virtual CNS Forum, scheduled for March 17-18. Here, the same three executives will again conduct a fireside chat, this time focused on the company's progress and prospects, on March 18 at 4:00 PM ET. Interested parties can also schedule one-on-one meetings during this virtual event by contacting their Stifel representatives or reaching out to Ms. Breu directly.
Immunic is advancing several critical programs, most notably vidofludimus calcium (IMU-838), which is undergoing phase 3 clinical trials for relapsing multiple sclerosis. There are high expectations for top-line data by the end of 2026. The company’s other therapeutic candidates include IMU-856 for gastrointestinal diseases and IMU-381, which is in preclinical testing for various autoimmune conditions.
This participation in investor conferences showcases Immunic’s commitment to transparency and investor engagement as it navigates the complexities of biotech development. For further details, stakeholders can visit Immunic's investor relations webpage.
MWN-AI** Analysis
Immunic, Inc. (Nasdaq: IMUX) presents a compelling case for investors as the company engages in strategic participation at several investor conferences in March 2026. This engagement highlights Immunic's commitment to transparency and investor relations, which can enhance investor confidence, particularly in a competitive biotechnology landscape.
The upcoming conferences—the Leerink Partners Global Healthcare Conference from March 8-11 and the Stifel 2026 Virtual CNS Forum on March 17-18—will feature key executives as they discuss the company’s innovative therapies, notably the lead program, vidofludimus calcium (IMU-838). As a late-stage biotechnology firm focusing on novel therapies for neurological and gastrointestinal diseases, Immunic’s communications during these events could offer critical insights into the progress of its Phase 3 clinical trials, which are expected to yield top-line data by the end of 2026.
Investors should keep a close eye on the details shared during the fireside chats as they often provide clarity on clinical outcomes, market positioning, and potential challenges. This information is crucial given the uncertainties surrounding drug development, regulatory approvals, and competition within the biotechnology sector. The company's focus on a first-in-class treatment approach may position it well, provided it can successfully navigate the complexities of the clinical trial landscape.
Moreover, with the potential for one-on-one investor meetings, interested parties have an excellent opportunity to engage directly with management, fostering a deeper understanding of the company's strategy and future trajectory.
In conclusion, investors looking for exposure in the biotechnology sector should consider Immunic's upcoming presentations as a significant opportunity to evaluate its potential growth. However, it is essential to remain mindful of the inherent risks within this space, making thorough due diligence a vital part of the investment process.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March:
- March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat on Wednesday, March 11, at 10:40 am ET at this conference in Miami. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt, Mr. Tardio and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: jessica.breu@imux.com.
- March 17-18: Stifel 2026 Virtual CNS Forum. Dr. Vitt and Mr. Tardio will participate in a fireside chat on Wednesday, March 18, at 4:00 pm ET at this virtual conference. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt, Mr. Tardio and Mrs. Breu will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Stifel representative or Jessica Breu at: jessica.breu@imux.com.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases such as celiac disease, inflammatory bowel disease, and Graft-versus-Host-Disease. IMU-381 comprises next-generation molecules in preclinical testing for neurologic, gastrointestinal and other autoimmune diseases leveraging the company's Nurr1 platform. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company's subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
ckasunich@kcsa.com
SOURCE Immunic, Inc.
FAQ**
How does Immunic Inc. (IMUX) plan to leverage the data from the ongoing phase 3 clinical trials of vidofludimus calcium for relapsing multiple sclerosis to enhance its market positioning and potential investor interest?
Can Immunic Inc. (IMUX) provide updates on any new findings related to the therapeutic activity of vidofludimus calcium in conditions beyond multiple sclerosis, such as other neurologic or gastrointestinal diseases?
What are the anticipated milestones for the development of IMU-856 in restoring intestinal barrier function, and how might these milestones impact Immunic Inc. (IMUX) in terms of funding and market opportunities?
Given the evolving landscape of biotechnology, how is Immunic Inc. (IMUX) addressing competitive pressures and regulatory challenges in the development of its novel oral therapies in the current market environment?
**MWN-AI FAQ is based on asking OpenAI questions about Immunic Inc. (NASDAQ: IMUX).
NASDAQ: IMUX
IMUX Trading
-4.41% G/L:
$1.1327 Last:
1,497,348 Volume:
$1.10 Open:
